Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
81,149,970
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
51,375,323
-
Shares change
-
+732,563
-
Total reported value, excl. options
-
$1,511,815,633
-
Value change
-
+$36,820,905
-
Put/Call ratio
-
217%
-
Number of buys
-
70
-
Number of sells
-
42
-
Price
-
$29.41
Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) as of Q3 2024
As of 30 Sep 2024 Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) had 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 51,375,323 shares of stock of the company.
Largest 10 holders included FMR LLC, Fairmount Funds Management LLC, RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, VR Adviser, LLC, BlackRock, Inc., VANGUARD GROUP INC, BRAIDWELL LP, COMMODORE CAPITAL LP, and STATE STREET CORP.
This table shows 118 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.